Fig. 4: In vivo efficacy of CART84 in an AML PDX model. | Leukemia

Fig. 4: In vivo efficacy of CART84 in an AML PDX model.

From: A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias

Fig. 4

A Experimental design. B Percentage of AML PDX cells in the peripheral blood of mice (n = 6 mice per group). Statistical analysis was performed with a two-way ANOVA with Dunnett’s multiple comparisons vs. control mice (Mean ± SEM). C Kaplan–Meier survival curves for each experimental group. Statistical significance was determined with a log-rank test, with a corrected p value for 3 comparisons (control vs.152.3 / 153.5; 152.3 vs. 153.5). D Percentage of AML PDX cells in the bone marrow or spleen of mice at the end of the experiment (Mean ± SD). Statistical analysis was performed with a one-way ANOVA with Dunnett’s multiple comparisons vs. the control group. ***p < 0.001, **p < 0.01, *p < 0.05.

Back to article page